By multivariate survival analysis, Bcl-2 positivity was associated with a longer disease-free interval (HR = 0.09, 95%-CI: 0.01–0.64; p = 0.017), a longer overall survival (HR = 0.28, 95%-CI: 0.11–0.72; p = 0.008), and a lower risk of cancer-related death (HR = 0.31, 95%-CI: 0.11–0.89; p = 0.031), as depicted in Table 4, with in each model, the pathologic tumor size and tumor-associated inflammation as the covariates. This evidence concerns the gene BCL2 and neoplasm.